FDA Broadens Breyanzi’s Follicular Lymphoma IndicationMay 16, 2024Non-Hodgkin LymphomaCellular TherapyIndolent Lymphoma
Survey Spotlights Identification of Dermatologic Adverse Events From Cancer TherapiesMay 13, 2024Mixed TopicsDLBCLPatient & Survivor CareCLLCMLAggressive LymphomasALL
Tiny Doses of Metabolically Armed CAR T Show BenefitsApril 23, 2024Cellular TherapyALLDLBCLNon-Hodgkin Lymphoma
Timing Is Everything: CAR T for Follicular LymphomaApril 18, 2024Non-Hodgkin LymphomaCellular Therapy
Most Targeted Cancer Drugs Lack Substantial Clinical BenefitApril 17, 2024DLBCLGene TherapyPatient & Survivor CarePediatricsMixed TopicsBusiness of MedicineALL
Less Than 50% of Accelerated Approvals Show Clinical BenefitApril 9, 2024DLBCLMixed TopicsPatient & Survivor CareAggressive LymphomasALLAMLB Cell Lymphoma
Abecma Approved for Earlier Lines in Relapsed/Refractory Multiple MyelomaApril 9, 2024Multiple MyelomaCellular Therapy
Secondary Cancers Post CAR T Therapy: A Concern?March 20, 2024Cellular TherapyAggressive LymphomasALLAMLAnemiaCLLCML
High Marks for New CAR T Toxicity Grading ToolMarch 12, 2024Cellular TherapyB Cell LymphomaDLBCLMantle Cell LymphomaMultiple MyelomaTransplantMixed Topics
